Abstract # 2125 Concurrent Chemoradiotherapy with Full-dose Gemcitabine for Unresectable Pancreatic Cancer

Presenter: Nakamura, Satoaki

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos

Between July 2001 and June 2006, 94 patients with unresectable pancreatic cancer were enrolled: stage I, II, III, and IV were 2, 21, 71, and 0, respectively. We treated with concurrent full-dose (1000 mg/m2, Days 1, 8, and 15 of a 28-day cycle) gemcitabine and radiotherapy using four-field or five-field conformal technique. The planned doses to deliver were 30 Gy (5 patients), 40 Gy (4 patients), and 50 Gy (85 patients), respectively, in daily 2-Gy fractions. The planning target volume (PTV) was limited to the gross target volume (GTV) plus 1-1.5 cm margin. After completion of irradiation, additional cycles of gemcitabine were delivered.